Abstract
With several specialities approved by EMA in the last years, targeted radionuclide therapy (TRT) is undergoing a strong development and treat more and more patients. Compared to previously approved radiopharmaceuticals (e.g. Zevalin™), treatments are now fractionated (several injections) and spread over several months. The absorbed dose and absorbed dose rate, the genetic and/or epigenetic characteristics of the tumours, but also the intercellular communications such as those involving the immune system, are becoming the key parameters to be considered in order to improve the effectiveness of the treatment while protecting healthy tissue. Radiobiology, using both preclinical models and a growing number of available clinical data, should provide rational insight into both the efficacy and toxicity of this continuous low dose rate radiotherapy form for better patient management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
